- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Cibus, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.03. | Cibus, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.03. | Cibus prices $15 million public offering at $2.15 per share | 2 | Investing.com | ||
| CIBUS Aktie jetzt für 0€ handeln | |||||
| 26.03. | Cibus stock dips after pricing $15M offering | 1 | Seeking Alpha | ||
| 26.03. | Cibus platziert Kapitalerhöhung über 15 Mio. US-Dollar zu 2,15 US-Dollar je Aktie | 3 | Investing.com Deutsch | ||
| 26.03. | Cibus, Inc.: Cibus, Inc. Announces Pricing of Public Offering of Class A Common Stock | 2 | GlobeNewswire (USA) | ||
| 25.03. | Cibus announces underwritten public offering of Class A shares | 2 | Investing.com | ||
| 25.03. | Cibus announces public offering of Class A common stock and pre-funded warrants | 1 | Seeking Alpha | ||
| 25.03. | Cibus, Inc.: Cibus, Inc. Announces Proposed Public Offering of Class A Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
| 18.03. | Cibus targets $200M annual rice royalties with expanded Latin America and India push while advancing biofragrance commercialization | 1 | Seeking Alpha | ||
| 17.03. | Cibus Q4 2025: Kostensenkungen stützen Aktie trotz höherem Verlust | 5 | Investing.com Deutsch | ||
| 17.03. | Cibus, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 17.03. | Cibus, Inc.: Cibus Reports Fourth Quarter Financial Results and Provides Business Update | 790 | GlobeNewswire (Europe) | SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies, today... ► Artikel lesen | |
| 17.03. | Cibus, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.02. | Cibus, Inc.: Cibus Partnering with The John Innes Centre for UK Government's Farming Innovation Programme Precision Breeding Initiative | 1 | GlobeNewswire (USA) | ||
| 29.01. | Cibus-Aktie fällt nach Preisfestsetzung für 20-Millionen-Dollar-Kapitalerhöhung | 4 | Investing.com Deutsch | ||
| 29.01. | Cibus prices public offering of 13.3 million shares at $1.50 each | 3 | Investing.com | ||
| 29.01. | Cibus legt Preis für Aktienemission fest: 13,3 Millionen Aktien zu 1,50 US-Dollar | 1 | Investing.com Deutsch | ||
| 29.01. | Cibus, Inc.: Cibus, Inc. Announces Pricing of $20.0 Million Public Offering of Class A Common Stock | 1 | GlobeNewswire (USA) | ||
| 28.01. | Cibus announces planned underwritten public offering of Class A shares; shares down | 3 | Seeking Alpha |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,40 | -0,06 % | BioNTech, Newron und Emyria: Biotech-Unternehmen rücken in den Fokus einer neuen Substanzdebatte | ||
| EVOTEC | 4,530 | +0,09 % | EQS-News: Evotec SE: Evotec nominiert Dieter Weinand als Aufsichtsratsvorsitzenden | EQS-News: Evotec SE
/ Schlagwort(e): Personalie
Evotec nominiert Dieter Weinand als Aufsichtsratsvorsitzenden
07.04.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| MODERNA | 43,330 | -0,30 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| PAION | 0,051 | -19,84 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| NOVAVAX | 6,860 | -1,01 % | Activist investor revives campaign to overhaul Novavax board | ||
| ILLUMINA | 102,88 | -0,23 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 17,950 | -3,49 % | Morning Market Movers: Super Micro Computer, Bimergen Energy, Palatin Technologies, Intellicheck See Big Swings | HONG KONG (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BRAIN BIOTECH | 2,470 | +1,23 % | EQS-News: BRAIN Biotech AG: BRAIN Biotech erhält bedeutendes Patent für seine CRISPR-BMC Genome-Editing-Technologie | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Patent
BRAIN Biotech erhält bedeutendes Patent für seine CRISPR-BMC Genome-Editing-Technologie
23.03.2026 / 11:05 CET/CEST
Für... ► Artikel lesen | |
| EDITAS MEDICINE | 2,430 | -3,19 % | Editas Medicine, Inc. - 8-K, Current Report | ||
| BIOCRYST PHARMACEUTICALS | 8,160 | +0,02 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen | |
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| IBIO | 1,841 | -0,32 % | iBio, Inc.: iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia | IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body compositionFirst participants expected to be dosed in 2Q 2026 SAN... ► Artikel lesen | |
| ATAIBECKLEY | 3,140 | +1,29 % | Depression und PTBS im Fokus: Wie Emyria und AtaiBeckley neue Wirtschaftsmodelle in der Psychiatrie prägen | ||
| TME PHARMA | 0,059 | 0,00 % | TME Pharma NV: TME Pharma extends financial runway to over 12 months | TME Pharma extends financial runway to over 12 months Berlin, Germany, March 9, 2025, 08.00am CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,215 | -3,19 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026 | King of Prussia, Pennsylvania--(Newsfile Corp. - April 9, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen |
Das Unternehmen CIBUS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +18,97 % bei einem Aktienkurs von 1,505 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CIBUS INC finden Sie auf Wallstreet Online.